Aspirin- MOA - ANSWER-Binds irreversibly to cyclooxyrgenase-1 and 2 (COX 1 and 2)
Decrease prostaglandin and thromboxane A2 production
Plavix
... [Show More] (clopidogrel) -MOA - ANSWER-Produg- irreversibly inhibits P2Y12 ADP-mediated platelet activation and aggregation
Boxed warning of Plavix - ANSWER-conversion to active metabolite require (CYP 450 2C19)
Poor metabolizers - higher CV events
Plavix- avoid to take with what - ANSWER-2c19 inhibitors (omeprazole, esomeprazole)
increased bleed
post CABG how long for antiplatelet therapy? - ANSWER-1 year
Post bare metal stent placement: how long for antiplatelet therapy? - ANSWER-1 month or less
Drug - eluting stent placement: how long for anti platelet therapy? - ANSWER-6 months or less
P2Y12 inhibitors MOA - ANSWER-Binds the adenosine diphosphate (ADP) P2Y12 receptor on the platelet surface
Prevents activation of the GPIIb/IIIa receptor complex
Reduces platelet aggregation
Brilinta - ANSWER-Not program; P2Y12 INHIBITOR DRUG
reversibly binds
P2Y12 inhibitor drugs - ANSWER-Plavix (clopidogrel)
Brinlinta (ticagrelor)
Effient (prasugrel)
Kengreal (cangrelor)
Glycoprotein 2b/3a receptor antagonist - ANSWER-Block platelet glycoprotein IIb/IIIa receptor (binding site for fibrinogen, von Willebrand factor, other ligands)
blocks platelet aggregation
******* prevents further thrombosis
Reversible blockades of Glycoprotein 3b/2a receptor antagonists - ANSWER-Integrilin (eptifibatide)
Aggrastat (tirofiban)
irreversible blockades of Glycoprotein 3b/2a receptor antagonists - ANSWER-ReoPro (abciximab)
what do Fibrinolytics do? - ANSWER-Breakdown clot by binding to fibrin in a clot
Converts entrapped plasminogen to plasma
When can you use fibrinolytics? - ANSWER-in confirmed STEMI
PCI preferred within 90 minutes door-to-balloon time or within 120 minutes from first medical contact
Fibrinolytic drugs - ANSWER-Activase (alteplase)** - recombinant tissue plasminogen activator (tPA, rtPA)
TNKase (tenecteplase)
Retavase (reteplase)
warnings for fibrinolytics - ANSWER-Severe uncontrolled hypertension (180/105) - unresponsive to emergency therapy (labetalol 1st line, nicardipine infusion if labetalol ineffective)
Protease-Activated Receptor-1 Antagonist drugs - ANSWER-Zontivity (vorapaxar)
Treatments that decrease mortality of HF - ANSWER-ACE Inhibitors or ARBs
BB
Angiotensin receptor agonista
Angiotensin receptor and nephprilsyin inhibitor
Treatments that decrease mortality of HF in select pts - ANSWER-BiDil - hydralazine and nitirate
Treatments that improve symptoms but with no proven effect on mortality - ANSWER-Loops diuretics
Digoxin
Corlandor (ivabradine) [Show Less]